CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...

A new study published in The Journal of Immunology found that a high-salt diet (HSD) induces depression-like symptoms in mice ...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

Agenus Inc. , a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25?30, 2025 in Chicago, ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...